New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3177-3184

  Villarroya, Mercedes ^a   Garcia A G ^a   Marco, J L ^b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

ACh; AChE BuChE inhibitors; AD; Amyloid ; Galanthamine; nAChR; Neurodegenerative diseases; Rivastigmine; Tacrine

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMINO ACID DERIVATIVE; AMIRIDINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHELATING AGENT; CHOLINERGIC RECEPTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CITICOLINE; DONEPEZIL; ESTRADIOL; ESTROGEN; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; NIMODIPINE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL 2; RIVASTIGMINE; ROFECOXIB; TACRINE; TACRINE DERIVATIVE; UNINDEXED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; APOPTOSIS; ATTENTION; BEHAVIOR; BRAIN ISCHEMIA; CALCIUM SIGNALING; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; COGNITION; DAILY LIFE ACTIVITY; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; MEMORY DISORDER; MEYNERT BASAL NUCLEUS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; HUMANS; REACTIVE OXYGEN SPECIES;

EID: 4544247386     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383368     Document Type: Review

References (91)

1. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399: A23-A31.
2. Standaert DG, Young AB. In Goodman and Gilman's The Pharmacological Basis of Therapeutics", 9th edition, McGraw-Hill, Mexico 1996; pp. 539-556.
3. Schröeder H, Lobron C, Wevers A, Maelick A, Giacobini E. In Alzheimer's and Parkinson's Disease: Recent Advances, Hanir I, Fiser A, Yashida M eds., Plenum Press, London 1995.
4. Belluardo N, Mudo G, Blum, M, Fuxe K. Central nicotinic receptors, neurotrophic factor and neuroprotection. Behav Brain Res 2000; 113: 21-34.
5. Donnely-Roberts DL, Xue IC, Arneric SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channels activator (ChCA), ABT-418. Brain Res 1996; 719: 36-44.
6. Yamashita H, Nakamura S. Nicotine rescues PC12 cells from death induced by nerve growth factor deprivation. Neurosci Lett 1996; 213: 145-147.
7. Shimohama S, Greenwald DL, Shafron DH, Akaika A, Maeda T, et al. Nicotinic α 7 receptors protect against glutamate neurotoxicity and neuronal ischaemic damage. Brain Res 1998; 779: 359-363.
8. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. β-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000; 275: 5626-5632.
9. Rusted JM, Newhouse PA, Levin ED. Nicotinic treatment for degenerative and neuropsyquiatric disorders such as Alzheimer's disease and Parkinson's disease. Behav Brain Res 2000; 113: 121-129.
10. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neurosci 1995; 64: 385-395.
11. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995; 9: 21-27.
12. Nordberg A. In vivo detection of neurotransmitter changes in Alzheimer's disease. Ann NY Acad Sci 1993; 695: 27-33.
13. Brenner DE, Kukull WA, Van Belle G, Bowen JD, McCormick WC, Teri L, et al. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology 1993; 43: 293-300.
14. Shalat SL, Seltzer B, Pidcock C, Baker EL Jr. Risk factors for Alzheimer's disease: a case-control study. Neurology 1987; 37: 1630-1633.
15. Giacobini E. Cholinergic receptors in human brain: effects of aging and Alzheimer's disease. J Neurosci Res 1990; 27: 548-560.
16. Summers KL, Giacobini E. Effects of local and repeated systemic administration of (-)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res 1995; 20: 753-759.
17. Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S, et al. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via α7-neuronal receptors and neuronal CNS receptors. Brain Res 1997; 765: 135-140.
18. Stevens TR, Krueger SR, Fitzsimonds RM, Picciotto MR. Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. Neurosci. 2003; 23: 10093-10099.
19. Newhouse PA, Sunderland T, Tariot PN, Blumbardt CL, Weingartner H, Mellow A, et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 1988; 95: 171-175.
20. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989; 154: 797-800.
21. Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behaviour. Neuropsychopharmacology 1994; 10: 93-107.
22. Decker Mw, Brioni Jd, Bannon Aw, Arneric Sp. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behaviour and implications for CNS therapeutics. Life Sci 1995; 56: 545-70.
23. Schroder H, Giacobini E, Struble RG, Zilles K, Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 1991; 12: 259-262.
24. Court JA, Perry EK. Dementia: the neurochemical basis of putative transmitter orientated therapy. Pharmacol Ther 1991; 52: 423-443.
25. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992; 4: 303-328.
26. Mattson M, Pedersen WA. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Devl Neurosci 1998; 16: 737-753.
27. Mattson M, Laferla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signalling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2000; 23: 222-229.
28. Etcheberrigaray R, Hirashima N, Nee L, Prince J, Govoni S, Racchi M, et al. Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol Dis 1998; 5: 37-45.
29. Paschen W. Dependence of vital cell function on endoplasmic reticulum calcium levels: implications for the mechanisms underlying neuronal cell injury in different pathological states. Cell Calcium 2001; 29: 1-11.
30. Wei H, Wei W, Bredesen DE, Perry DC. Bcl-2 protects against apoptosis in neuronal cell line caused by thapsigargin-induced depletion of intracellular calcium stores. Neurochem 1998; 70: 2305-2314.
31. Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J, et al. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol 1999; 1: 479-485.
32. Kirischuk S, Verkhratsky A. Calcium homeostasis in aged neurons. Life Sci 1996; 59: 451-459.
33. Querfurth HW, Selkoe DJ. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry 1994; 33: 4550-4561.
34. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, et al. Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides. Nat Med 1997; 3: 1016-1020.
35. Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localisation to intracellular membranes in mammalian cells. Nat Med 1996; 2: 224-229.
36. Engstrom I, Ronquist G, Pettersson L, Waldenstrom A. Alzheimer amyloid beta-peptides exhibit ionophore-like properties in human erythrocytes. Eur J Clin Invest 1995; 25: 471-476.
37. Pollard HB, Arispe N, Rojas E. Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Cell Mol Neurobiol 1995; 15: 513-526.
38. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-1245.
39. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl) 1993; 110: 395-401.
40. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
41. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997; 10: 234-239.
42. Scott LJ, Goa KL. Galanthamine: a review of its use in Alzheimer's disease. Drugs 2000; 60: 1095-1122.
43. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993; 98: 431-438.
44. Dovey HE, John V, Anderson JP, Chen LZ, De Saint Andrieu P, Fang LY, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-181.
45. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995; 6: 633-636.
46. Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 2001; 15: 85-91.
47. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996; 19: 497-506.
48. Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, et al. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and β-amyloid pathologies. Neuroscience 1999; 92: 499-513.
49. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147.
50. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 1992; 186: 944-950.
51. Thal L J. Clinical and preclinical information of anti-oxidants: Idebenone and vitamin E. Neurobiol Aging 1998; 19: 20.
52. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140: 256-261.
53. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, et al. Estrogen reduces neuronal generation of Alzheimer amyloid peptides. Nat Med 1998; 4: 447-451.
54. Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 2000; 107: 203-231.
55. Lipton SA. Janus faces of NF-κB: neurodestruction versus neuroprotection. Nat Med 1997; 3: 20-22.
56. Lipsky RH, Xu K, Zhu D, Kelly C, Terhakopian A, Novelli A, et al. Nuclear factor κB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotection. J Neurochem 2001; 78: 254-264.
57. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995; 6: 1053-1057.
58. Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol 1996; 6: 493-506.
59. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
60. Arias E, Ales E, Gabilan NH, Cano-Abad ME, Villarroya M, Garcia AG, et al. Galanthamine prevents apoptosis induced by β -amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004; 46: 103-114.
61. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003; 306: 772-777.
62. Farber SA, Slack BE, Blusztajn JK. Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease. FASEB J 2000; 14: 2198-2206.
63. Alvarez XA, Mouzo R, Pichel V, Perez P, Laredo M, Fernandez-Novoa L, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 1999; 21: 633-644.
64. Crowther RA, Wischik CM. Image reconstruction of the Alzheimer paired helical filament. EMBO J 1985; 4: 3661-3665.
65. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 2000; 485: 87-93,
66. Mcgeer EG, Mcgeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 1999; 5: 821-836.
67. Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000; 27: 1-8.
68. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-5714.
69. Blain H, Jouzeau JY, Blain A, Terlain B, Trechot P, Touchon J, et al. Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives. Presse Med 2000; 29: 267-273,
70. Haass C, De Strooper B. The presenilins in' Alzheimer's disease- proteolysis holds the key. Science 1999; 286: 916-919.
71. Geula C, Mesulam M. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res 1989; 498: 185-189.
72. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C, et al. Acety1cholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-891.
73. Álvarez A, Opazo C, Alarcón R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid β-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272: 348-361.
74. Inestrosa NC, Álvarez A, Godoy J, Reyes A, De Ferrari GV. Acetylcholinesterase-amyloid-β-peptide interaction and Wnt signaling involvement in Aβ neurotoxicity. Acta Neurol Scand 2000; 176: 53-59.
75. Bartolini M, Bertucci C, Cavrini V, Andrisano V. β-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003; 65: 407-416.
76. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 1994; 37: 777-787.
77. Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid β-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res Mol 1998; 62: 131-140.
78. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A. Ge YW, et al. Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001; 98: 7605-7610.
79. Boyt AA, Suzuky T, Hone E, Gnjec A, Martins RM. The structure and multifaceted function of the amyloid precursor protein. Clin Biochem Rev 2000; 21: 22-41.
80. Bonner LT, Peskind ER. Pharmacologic treatment of dementia. Medical Clinics of North America 2002; 86: 657-674.
81. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002; 109: 1053-1065.
82. Siek GC, Katz LS, Fishman EB, Korosi TS, Marquis JK. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry 1990; 27: 573-580.
83. Weinstock M, Razin M, Chorev M, Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm Suppl 1994; 43: 219-225.
84. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque E. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000; 113: 199-206.
85. Marco J L, De Los Ríos C, Carreiras MDC, Baõs JE, Badía A, Vivas N. Synthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of new tacrine-like analogues. Bioorg Med Chem 2001; 9 (Suppl. 3): 727-732.
86. De Los Ríos C, Marco J L, Carreiras MDC, Chinchón PM, García AG, Villarroya M. Novel tacrine derivatives that block neuronal calcium channels. Bioorg Med Chem 2002; 10: 2077-2088.
87. Canti C, Bodas E, Marsal J, Solsona C. Tacrine and physostigmine block nicotinic receptors in Xenopus oocytes injected with Torpedo electroplaque membranes. Eur J Pharmacol 1998; 363: 197-202.
88. Villarroya M, De La Fuente MT, López MG, Gandía L, Garcia AG. Distinct effects of ω-toxins and various groups of Ca(2+)-entry inhibitors on nicotinic acetylcholine receptor and Ca2+ channels of chromaffin cells. Eur J Pharmacol 1997; 320: 249-57.
89. Campiani G, Fattorusso C, De Angelis M, Catalanotti B, Butini S, Fattorusso R, el al. Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases. Curr Pharm Design 2003; 9(8): 599-625.
90. Covelli V, Pellegrino NM, Jirillo E. A point of view: The need to identify an antigen in psyconeurommumological disorders. Curr Pharm Design 2003; 9(24): 1951-5.
91. Hersh LB. Peptidases, proteases and amyloid beta-peptide catabolism. Curr Pharm Design 2003; 9(6): 449-54.